Lataa...
Overcoming acquired resistance of EGFR-mutant NSCLC cells to osimertinib by combining osimertinib with the HDAC inhibitor, panobinostat (LBH589)
BACKGROUND: The major clinical obstacle that limits the long-term benefits of treatment with osimertinib (AZD9291 or TAGRISSO™) in patients with EGFR-mutant non-small cell lung cancer (NSCLC) is the development of acquired resistance. Therefore, effective strategies that can overcome osimertinib acq...
Tallennettuna:
| Julkaisussa: | Cancer |
|---|---|
| Päätekijät: | , , , , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
2020
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7241261/ https://ncbi.nlm.nih.gov/pubmed/31999837 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.32744 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|